The drive to reduce opioid use has led patients to clinics offering off-label painkiller injections. Pfizer asked the F.D.A. to ban the treatment years ago.
Simon & Schuster plans to publish “Fear: Trump in the White House,” on Sept 11. The book is Mr. Woodward’s 19th.
As second-quarter earnings pour in, executives are telling investors that they can raise prices to offset the impact of tariffs.
Conventional wisdom says the two companies should be blocked from merging to preserve competition and benefit consumers. But the merger could actually create a mightier maverick.
Legislators, officials and activists around the country are rushing to stop a company from posting blueprints for 3-D printed guns this week.
Chris Pratt and other stars derided the “mob mentality” that led Disney to oust the writer-director James Gunn. But just how should studios handle transgressions made during a more anything-goes era?
A U.S. senator and a panel in Britain’s House of Commons have offered some of the first firm suggestions to address issues relating to privacy and misinformation.
Tensions between 7-Eleven and its franchisees have simmered for years. Now, they’re boiling over as store owners face a new franchise agreement that they say will shrink their profits further.
A Supreme Court ruling gave the agency a five-year window to seek repayment of money. Can it speed up its work, or will it need to ask Congress to act?
It’s often too complicated. And even when it isn’t, almost no one does it.